O ROURKE & COMPANY Inc Has $620,000 Stock Position in Waters Co. (NYSE:WAT)

O ROURKE & COMPANY Inc lessened its holdings in Waters Co. (NYSE:WAT) by 3.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,670 shares of the medical instruments supplier’s stock after selling 62 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Waters were worth $620,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Advisory Alpha LLC lifted its holdings in Waters by 2.6% during the fourth quarter. Advisory Alpha LLC now owns 1,065 shares of the medical instruments supplier’s stock valued at $395,000 after purchasing an additional 27 shares during the last quarter. Empowered Funds LLC boosted its holdings in Waters by 3.0% in the 4th quarter. Empowered Funds LLC now owns 966 shares of the medical instruments supplier’s stock worth $358,000 after buying an additional 28 shares during the period. Deroy & Devereaux Private Investment Counsel Inc. grew its stake in Waters by 0.3% in the 4th quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 9,610 shares of the medical instruments supplier’s stock valued at $3,565,000 after buying an additional 30 shares in the last quarter. Blue Trust Inc. raised its holdings in Waters by 9.6% during the 4th quarter. Blue Trust Inc. now owns 353 shares of the medical instruments supplier’s stock valued at $127,000 after acquiring an additional 31 shares during the period. Finally, Larson Financial Group LLC lifted its position in shares of Waters by 6.8% during the fourth quarter. Larson Financial Group LLC now owns 537 shares of the medical instruments supplier’s stock worth $199,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on WAT. Robert W. Baird upgraded Waters from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $396.00 to $407.00 in a research note on Wednesday, March 26th. UBS Group upped their price target on Waters from $405.00 to $410.00 and gave the company a “neutral” rating in a research report on Thursday, February 13th. Barclays cut their price objective on shares of Waters from $400.00 to $350.00 and set an “equal weight” rating for the company in a research report on Thursday. Baird R W raised shares of Waters from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 26th. Finally, Wells Fargo & Company increased their target price on shares of Waters from $415.00 to $420.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Waters currently has a consensus rating of “Moderate Buy” and a consensus price target of $397.25.

Waters Stock Up 3.4 %

NYSE:WAT opened at $325.44 on Friday. The company has a market cap of $19.33 billion, a price-to-earnings ratio of 30.39, a price-to-earnings-growth ratio of 3.79 and a beta of 1.04. Waters Co. has a twelve month low of $279.24 and a twelve month high of $423.56. The company has a current ratio of 0.94, a quick ratio of 0.65 and a debt-to-equity ratio of 1.14. The stock has a fifty day simple moving average of $368.81 and a 200-day simple moving average of $372.37.

Waters (NYSE:WAT) last announced its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a return on equity of 46.31% and a net margin of 21.56%. Analysts anticipate that Waters Co. will post 12.86 EPS for the current year.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.